These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 25653196)

  • 41. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
    Kanda R; Kawahara A; Watari K; Murakami Y; Sonoda K; Maeda M; Fujita H; Kage M; Uramoto H; Costa C; Kuwano M; Ono M
    Cancer Res; 2013 Oct; 73(20):6243-53. PubMed ID: 23872583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.
    Nashed M; Chisholm JW; Igal RA
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1007-17. PubMed ID: 22946088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
    Day TF; Kallakury BVS; Ross JS; Voronel O; Vaidya S; Sheehan CE; Kasid UN
    Mol Cancer Res; 2019 May; 17(5):1207-1219. PubMed ID: 30647104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve.
    Er EE; Mendoza MC; Mackey AM; Rameh LE; Blenis J
    Sci Signal; 2013 Jun; 6(279):ra45. PubMed ID: 23757022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
    Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
    Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
    Ueda S; Basaki Y; Yoshie M; Ogawa K; Sakisaka S; Kuwano M; Ono M
    Cancer Res; 2006 May; 66(10):5346-53. PubMed ID: 16707461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
    Sos ML; Zander T; Thomas RK; Staratschek-Jox A; Claasen J; Wolf J
    J Thorac Oncol; 2008 Feb; 3(2):170-3. PubMed ID: 18303439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
    Sevelda F; Mayr L; Kubista B; Lötsch D; van Schoonhoven S; Windhager R; Pirker C; Micksche M; Berger W
    J Exp Clin Cancer Res; 2015 Nov; 34():134. PubMed ID: 26526352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
    Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
    Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
    Zhang G; Fang T; Chang M; Li J; Hong Q; Bai C; Zhou J
    Oncol Rep; 2018 Oct; 40(4):1937-1946. PubMed ID: 30106446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decoupling of receptor and downstream signals in the Akt pathway by its low-pass filter characteristics.
    Fujita KA; Toyoshima Y; Uda S; Ozaki Y; Kubota H; Kuroda S
    Sci Signal; 2010 Jul; 3(132):ra56. PubMed ID: 20664065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
    Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
    Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation.
    Liu B; Su Y; Li T; Yuan W; Mo X; Li H; He Q; Ma D; Han W
    Oncotarget; 2015 Dec; 6(38):41092-107. PubMed ID: 26528697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EGF stimulates the activation of EGF receptors and the selective activation of major signaling pathways during mitosis.
    Wee P; Shi H; Jiang J; Wang Y; Wang Z
    Cell Signal; 2015 Mar; 27(3):638-51. PubMed ID: 25479591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.